...at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

ABOUT HANSA BIOPHARMA

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer. The Company's lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the first quarter 2021. Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and has operations in EU and the US.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES

Candidate	Indication	Research/ Preclinical	Phase 1	Potentially Pivotal program/ Phase 2	Phase 3	Marketing Authorization	Marketed
Imlifidase	**EU** Kidney transplantation in highly sensitized patients [1,2]						*)
	US Kidney transplantation in highly sensitized patients [1,2]				**)		
	Anti-GBM antibody disease (investigator-initiated study)						
	Antibody mediated kidney transplant rejection (AMR)						
	GBS (Guillain Barre Syndrome)						
	Limb-Girdle (LGMD) & Duchenne (DMD) (Pre-treatment ahead of gene therapy with Sarepta)						
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology						
EnzE	Cancer immunotherapy						

Completed
Ongoing

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
3 Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch
**) FDA: Proposed study protocol submitted June 2020. Discussions are currently ongoing with the FDA. Once the final protocol has been agreed upon, Hansa Biopharma will proceed to set up centers in the US and start to enroll patients. Given the continued impact of the COVID-19 pandemic and the timeline for the finalization of the study protocol Hansa expect recruitment of the first patient to be in H1 2021)

STRATEGIC PRIORITIES

- Establish a commercial and medical infrastructure in Europe
- Marketing authorization obtained in Europe for imlifidase as a treatment for highly sensitized patients to enable kidney transplantation. Conduct a new randomized, controlled study in the US in the context of KAS to support a BLA filing by 2023
- Investigate the potential of imlifidase in autoimmune indications and post transplantation
- Advance a new set of immunomodulatory enzymes designed for repeat dosing in relapsing diseases (NiceR) into clinical development
- Explore potential combination therapies with imlifidase in oncology and in gene therapy in patients with neutralizing antibodies

ANTICIPATED FUTURE MILESTONES



Updated 2020-10-22

Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund, Sweden
www.hansabiopharma.com

HANSA BIOPHARMA

COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HNSA)
Headquarter	Lund, Sweden
Operations	Europe and the US
Employees	~100 (~2/3 in R&D)
Key Executives	Ulf Wiinberg, Chairman Søren Tulstrup, President & CEO Donato Spota, SVP & CFO Christian Kjellman, SVP & CSO/COO

MARKET DATA (Q4 2020)

Market Cap	SEK ~11bn (USD ~1.25bn)
52 Week Range	SEK 59-289
Avg. Daily Turnover	vol. 394k shares
Shares Outstanding	45m
Top 5 Shareholders	Redmile Group 10.4% Consonance Capman 5.0% NXT2B 4.8% Invesco 4.5% Handelsbanken Fonder 4.4%

STOCK CHART (1Y)



KEY FINANCIALS

SEKm	2018	2019	2020*
Revenue	3m	3m	6m
R&D cost	-155m	-193m	-227m
Net loss	-258m	-360m	-421m
Cash & Short investment	858m	601m	1,378m
Operating Cash Flow	-205m	-335m	-290m
Employees	52	74	87

** Unaudited*

CALENDAR

Feb 10, 2021	Vator Swiss Nordic Conference (virtual)
Mar 9, 2021	Carnegie Nordic Healthcare Seminar (virtual)
Mar 25, 2021	Bryan Garnier Kidney event (virtual)
April 1, 2021	Guggenheim Healthcare Talks (virtual)
April 7, 2021	ABG Small & Midcap seminar Copenhagen
April 8, 2021	**Annual Report 2020**
April 22, 2021	**Interim report for Jan-Mar 2021**
May 5, 2021	Kempen Life Sciences Conference (virtual)
May 19, 2021	RBC Global Healthcare Conference
June 1, 2021	Jefferies Healthcare Conference

CONTACTS

Klaus Sindahl
Head of Investor Relations
M: +46(0)709-298 269
klaus.sindahl@hansabiopharma.com

Katja Margell
Head of Corp. Comms.
M: +46(0)768-198 326
katja.margell@hansabiopharma.com

IMLIFIDASE – A NOVEL APPROACH TO ELIMINATE PATHOGENIC IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection

Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Imlifidase inactivates IgG in 2 hours

- Rapid onset of action that inactivates IgG below detectable level in 2 hours
- IgG antibody-free window for approximately one week



OUR EQUITY STORY



POTENTIAL INDICATION UNIVERSE



* US: Study protocol submitted June 2020, study expected to be initiated H1 2021. The new clinical study could support BLA submission by 2023